Literature DB >> 9715405

Serum N-acetylglucosaminyltransferase III activities in hepatocellular carcinoma.

S Mori1, Y Aoyagi, M Yanagi, Y Suzuki, H Asakura.   

Abstract

N-Acetylglucosaminyltransferase III (GnT III) catalyses the addition of N-acetylglucosamine through a beta 1-4 linkage to the mannose of the trimannosyl core, resulting in conversion of the concanavalin A (Con A)-reactive glycan into a non-reactive state. In this study, we measured GnT III activity to evaluate its diagnostic efficacy and its therapeutic effect on hepatocellular carcinoma (HCC). Concanavalin A-non-reactive fraction of serum transferrin (Tf) was also determined since the sugar chains of Tf are one of the possible candidates for the product of GnT III. Serum samples (159) were used from patients with HCC (89), liver cirrhosis (30), chronic hepatitis (19), alpha-fetoprotein (AFP) producing gastric carcinoma metastatic to the liver (five) and healthy controls (16). N-Acetylglucosaminyltransferase III activity was determined by high performance liquid chromatography. The reactivity of serum Tf to Con A was also analysed in 21 paired HCC samples before and after treatment by crossed immuno-affinoelectrophoresis. N-Acetylglucosaminyltransferase III activity from the HCC group (153 +/- 72pmol/mL/h) was significantly higher than that from liver cirrhosis (99 +/- 67 pmol/mL per h), chronic hepatitis (84 +/- 39 pmol/mL per h) and the normal controls (62 +/- 16 pmol/mL per h). N-Acetylglucosaminyltransferase III activity of 21 patients with HCC was significantly reduced after treatment such as transcatheter arterial chemoembolization and/or percutaneous ethanol infection therapy, (123 +/- 77 to 100 +/- 60 pmol/mL per h). Commensurate decreases of AFP and des-gamma-carboxy prothrombin with GnT III activity were also observed after treatment. The Con A-non-reactive fraction (n = 21; 6.4 +/- 2.3%) in patients with HCC after treatment was significantly lower than before (8.2 +/- 2.4%). The present study suggests that GnT III activity is a possible aid in the diagnosis and evaluation of HCC, especially when other tumour markers are negative.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715405     DOI: 10.1111/j.1440-1746.1998.tb00699.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

Review 1.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

2.  Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring.

Authors:  Petra Darebna; Petr Novak; Radek Kucera; Ondrej Topolcan; Miloslav Sanda; Radoslav Goldman; Petr Pompach
Journal:  J Proteomics       Date:  2016-09-16       Impact factor: 4.044

3.  Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.

Authors:  Petr Pompach; Zuzana Brnakova; Miloslav Sanda; Jing Wu; Nathan Edwards; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-06       Impact factor: 5.911

4.  Antibodies that recognize bisected complex N-glycans on cell surface glycoproteins can be made in mice lacking N-acetylglucosaminyltransferase III.

Authors:  JaeHoon Lee; Sung-Hae Park; Pamela Stanley
Journal:  Glycoconj J       Date:  2002-03       Impact factor: 2.916

5.  Determination of UDP-N-acetylglucosamine: beta-D-mannoside-1,4-N-acetylglucosaminyltransferase-III in patients sera with chronic hepatitis and liver cirrhosis using a monoclonal antibody.

Authors:  Eun-Young Song; Kyung-Sook Kim; Kyoung-A Kim; Yung-Dai Kim; Dur-Han Kwon; Si-Myung Byun; Hee-Jung Kim; Tae-Wook Chung; Yong-Kyung Choe; Tai-Wha Chung; Cheorl-Ho Kim
Journal:  Glycoconj J       Date:  2002-07       Impact factor: 2.916

6.  Protein and site specificity of fucosylation in liver-secreted glycoproteins.

Authors:  Petr Pompach; David J Ashline; Zuzana Brnakova; Julius Benicky; Miloslav Sanda; Radoslav Goldman
Journal:  J Proteome Res       Date:  2014-10-10       Impact factor: 4.466

7.  The glycomic effect of N-acetylglucosaminyltransferase III overexpression in metastatic melanoma cells. GnT-III modifies highly branched N-glycans.

Authors:  Paweł Link-Lenczowski; Monika Bubka; Crina I A Balog; Carolien A M Koeleman; Terry D Butters; Manfred Wuhrer; Anna Lityńska
Journal:  Glycoconj J       Date:  2018-03-03       Impact factor: 2.916

8.  A Potential Serum N-glycan Biomarker for Hepatitis C Virus-Related Early-Stage Hepatocellular Carcinoma with Liver Cirrhosis.

Authors:  Mikito Higashi; Takeshi Yoshimura; Noriyoshi Usui; Yuichiro Kano; Akihiro Deguchi; Kazuhiro Tanabe; Youichi Uchimura; Shigeki Kuriyama; Yasuyuki Suzuki; Tsutomu Masaki; Kazuhiro Ikenaka
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.